<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03708588</url>
  </required_header>
  <id_info>
    <org_study_id>18-078_18-911</org_study_id>
    <nct_id>NCT03708588</nct_id>
  </id_info>
  <brief_title>Chewed Versus Integral Pill of Ticagrelor</brief_title>
  <official_title>Chewed Versus Integral Pill of Ticagrelor in All Patients Undergoing Percutaneous Coronary intervention--a Platelet Reactivity and Patient Outcomes Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurora Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurora Health Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis The primary question the investigators propose to answer is whether all patients
      undergoing PCI with stent deployment who receive chewed ticagrelor will demonstrate more
      rapid drug absorption and decreased platelet reactivity as compared to integral pill form 1
      hour after drug administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis The primary question the investigators propose to answer is whether all patients
      undergoing PCI with stent deployment who receive chewed ticagrelor will demonstrate more
      rapid drug absorption and decreased platelet reactivity as compared to integral pill form 1
      hour after drug administration.

      Secondary Hypotheses:

        1. Major adverse cardiac and cerebrovascular event (MACCE) rate at 30 days and 1 year.

             1. Death

             2. Repeat myocardial infarction

             3. Need for urgent revascularization

             4. Cerebrovascular accident

        2. Rate of stent thrombosis and in-stent stenosis at 30 days and 1 year.

        3. Bleeding: Defined as major, minor, or minimal bleeding based on TIMI criteria.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 19, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of pharmacodynamics</measure>
    <time_frame>1 hour</time_frame>
    <description>Measure platelet reactivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Major adverse cardiac and cerebrovascular event MACCE</measure>
    <time_frame>30 days</time_frame>
    <description>Measure events such as: death, repeat myocardial revascularization, cerebrovascular accident, stent thrombosis, in-stent stenosis and bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Major adverse cardiac and cerebrovascular event MACCE</measure>
    <time_frame>1 year</time_frame>
    <description>Measure events such as: death, repeat myocardial revascularization, cerebrovascular accident, stent thrombosis, in-stent stenosis and bleeding.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Experimental: Chewed ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Ticagrelor chewed pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline PRU level is drawn and before the end of the PCI. Patients will be asked to chew, but not swallow, allowing for sublingual absorption. (Loading dose 180mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Integral pill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Ticagrelor integral pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline PRU level is drawn and before the end of the PCI. Patients will swallow the loading dose followed by 25-50mL of water. (180mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Chewed</description>
    <arm_group_label>Experimental: Chewed ticagrelor</arm_group_label>
    <other_name>Brilinta</other_name>
    <other_name>Brilique</other_name>
    <other_name>Possia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Integral</description>
    <arm_group_label>Active Comparator: Integral pill</arm_group_label>
    <other_name>Brilinta</other_name>
    <other_name>Brilique</other_name>
    <other_name>Possia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ All patients presenting to the cardiac catheterization lab for percutaneous coronary
        intervention.

        Exclusion Criteria:

          -  Age &lt;18 years or Age &gt;89 years

          -  Known coagulopathy, bleeding diathesis, or active bleeding

          -  History of recent gastrointestinal or genitourinary bleed within 2 months

          -  Known chronic therapy with clopidogrel, prasugrel, or ticagrelor

          -  Major surgery within last 6 weeks

          -  History of intracranial bleed or intracranial neoplasm

          -  Suspected aortic dissection

          -  Severe hemodynamic instability, cardiogenic shock

          -  Life expectancy &lt;1 year

          -  Known severe liver or renal disease

          -  Known HIV treatment

          -  Any use of GP IIb-IIIa inhibitors 48-hours before the procedure or any use during the
             procedure

          -  Any use of Cangrelor during or after the procedure

          -  Hemoglobin &lt;10 g/dL, PLT &lt;100x10^9/L

          -  Pregnancy

          -  Known allergy to study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas F Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aurora Health Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aurora Health Care, St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aurora Health Care</investigator_affiliation>
    <investigator_full_name>Thomas F. Wilson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ticagrelor</keyword>
  <keyword>Stent</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

